Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

Female Pattern Baldness Clinical Trial

— GENERA  

Official title:

Phase III, National, Multicenter, Randomized, Double-Blind, Superiority Clinical Trial to Evaluate the Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05824065
• Other study ID #: OMA102-III-0123
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: January 2025
• Est. completion date: January 2027

Study information

• Verified date: April 2023
• Source: EMS
• Contact: Cassiano Ricardo O Berto, B.S.
• Phone: +551938877724
• Email: pesquisa.clinica[@]ncfarma.com.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 504
• Est. completion date: January 2027
• Est. primary completion date: January 2027
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;

• Age greater than 18 and equal or under 50 years;

• Confirmed diagnosis of female pattern hair loss, grade II to IV in Sinclair Scale;

• Participants that are disposed to maintain the same hair color, style, approximate hair length throughout the Clinical Study.

Exclusion Criteria:

• Any clinical or physical finding interpreted by the investigator as a risk to subject participation in the Clinical Study

• History of alcohol or illicit drugs abuse in the last year;

• Pregnant or breastfeeding women, who are planning to become pregnant or participants who have childbearing potential and are not using any reliable contraceptive method;

• Allergy or sensibility to any knowing components of the formula;

• Diagnosis of arterial hypertension;

• History of vasovagal syncope;

• Baseline systolic blood pressure lower than 90 mmHg and/or diastolic lower than 60 mmHg;

• Diagnosis of orthostatic hypotension (reduction of systolic blood pressure equal or superior to 20 mmHg and/or diastolic equal or superior to 10 mmHg after 3 minutes in orthostatic position);

• Body mass index (BMI) > 30 kg/m²;

• Subjects that initiated any kind of continue use medication, including contraceptives with systemic effect, until 3 months previously the inclusion in the Clinical Study;

• History of cardiovascular, liver and renal diseases;

• History of hypothyroidism, hyperthyroidism or pheochromocytoma;

• Signs or symptoms of cardiopathy or angina;

• History of edema from any etiology;

• Participants who are using tricycle antidepressants, benzodiazepines, antipsychotics, anticholinergics, sulfonamide derivatives, beta-blockers, sympathomimetics, arginine, glucocorticoid or monoamine oxidase inhibitors;

• Use of inhibitor of 5-alpha reductase or androgenic blockers in the last 12 months;

• Dermatologic diseases of the scalp, except mild seborrheic dermatitis or diagnosis of any kind of alopecia other than female pattern hair loss;

• History of surgical treatment for hair loss or presence of shaved scalp;

• Scalp microinfusion, microneedling or intradermotherapy in the last 3 years;

• Vaginal or cesarean deliveries 6 months before the inclusion in the study;

• Drastic modification of habitual diet, as food restrictions or hyperselectivity;

• Current cancer or history of cancer in the last 5 years;

• Participation in others research protocols in the last 12 months, unless the investigator judges that there may be a direct benefit to the participant.

Related Conditions & MeSH terms

• Alopecia
• Female Pattern Baldness

Intervention

Drug:
• OMA102
1 mg
• OMA102
2 mg
• Placebo
OMA102 - Placebo

Locations

Country	Name	City	State
Brazil	EMS	Hortolândia	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
EMS

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.	Variation of hair in the mid-front area after 6 months of treatment in comparison to baseline, assessed by digital phototrichogram.	6 months
Secondary	Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.	Variation of hair in the mid-front area after 3 months of treatment in comparison to baseline, assessed by digital phototrichogram.	3 months
Secondary	Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of non vellus and vellus hair growth, in the mid frontal area, assessed by digital phototrichogram.	Variation of non vellus and vellus hair in the mid-front area after 3 and 6 months of treatment in comparison to baseline, assessed by digital phototrichogram.	3 and 6 months
Secondary	Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Clinical Global Impression of Improvement (CGI-I) by the investigator perception.	Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement global photographs assessed by Clinical Global Impression of Improvement (CGI-I) by the investigator perception, 3 and 6 months after treatment.	3 and 6 months
Secondary	Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Patient Global Impression, PGI-I, by the subject perception.	Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of Global Photographs assessed by Patient Global Impression PGI-I, by the investigator perception, 3 and 6 months after treatment.	3 and 6 months
Secondary	Efficacy of OMA102 1 mg and OMA102 2 mg in quality of life, assessed by Women's Androgenetic Alopecia Quality of Life (WAA-QoL).	Efficacy of OMA102 1 mg and OMA102 2 mg in quality of life, assessed by Women's Androgenetic Alopecia Quality of Life (WAA-QoL) in comparison to baseline, 3 and 6 months after treatment.	3 and 6 months